NantKwest announces Phase 1 results of PD-L1.t-haNK cell therapy
Category: #health  By Mateen Dalal  Date: 2019-12-04
  • share
  • Twitter
  • Facebook
  • LinkedIn

NantKwest announces Phase 1 results of PD-L1.t-haNK cell therapy

NantKwest Inc., a U.S.-based clinical-stage immunotherapy company, has reportedly announced encouraging safety data generated from the first six patients in its QUILT-3.064 clinical trial. The study is conducted to access the preliminary efficacy and safety of PD-L1.t-haNK cell therapy in patients who are suffering from metastatic or locally advanced solid tumors. 

PD-L1.t-haNK cells are allogeneic, human-derived, natural killer cell line developed to express CAR (chimeric antigen receptor) targeting PD-L1. It is developed to generate intracellular IL-2 for increased CD16-targeted antibody-reliant cellular cytotoxicity capabilities.

According to Dr. Patrick Soon-Shiong, Chairman and CEO of NantKwest, the dual targeting of PD-L1.t-haNK to both therapeutic monoclonal antibodies and PD-L1 expressing tumors could become a transformative treatment for advanced solid tumors with cell-based therapies.

PD-L1.t-haNK is an off-the-shelf, cryopreserved product that can quickly deliver therapy to patients in an outpatient setting. It prevents the extensive manufacturing delays related to autologous CAR-T therapies. 

Soon-Shiong added that their company is looking forward to reporting full study results from the Phase 1 cohort and are moving towards the recommended Phase 2 dose. NantKwest would advance its innovative cell therapies like PD-L1.t-haNK with ImmunityBio’s N-803, a IL-15 superagonist developed to stimulate proliferation and activation of NK cells to boost the potential of immunogenic cell death for treating cancer, said Soon-Shiong.

For the record, NantKwest and a fully owned subsidiary of ImmunityBio has collaborated to co-develop off-the-shelf NK platforms with N-803.

John Lee, M.D., Clinical Senior Vice President, NantKwest, states that the company is encouraged with the safety results of PD-L1.t-haNK in patients who are suffering from difficult to treat solid tumors. All six patients were able to be infused in the outpatient setting without showing immune-related adverse events or cytokine toxicities, said Lee. 

Moreover, the company’s approach is designed to overcome the limitations and challenges seen while treating solid tumors with CAR-T and other immunotherapy advances. It is also looking forward to progressing studies to advance this innovative new approach to cancer treatment.
 

Source Credit - https://nantkwest.com/nantkwest-announces-phase-1-results-for-first-in-human-pd-l1-tumor-targeted-natural-killer-cells-pd-l1-t-hank-in-patients-with-locally-advanced-or-metastatic-solid-cancers/

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Microsoft investigates Teams and Outlook outage that left users disrupted
Microsoft investigates Teams and Outlook outage that left users disrupted
By Mateen Dalal

Microsoft, the U.S.-based technology frontrunner, reportedly investigating an outage that prevented thousands of customers from accessing services like Teams and Outlook. Apparently, the tech giant did not disclose the number of users that were im...

DeHaat secures $60 million in funding, tops $700 million valuation
DeHaat secures $60 million in funding, tops $700 million valuation
By Mateen Dalal

Indian agritech firm DeHaat has reportedly raised $60 million in a new funding round as it looks forward to strengthening its footprint in the country and touching break-even profitability in two years. For the unversed, the startup provides a range ...

Sensorium registers new branch in UAE to expand global presence
Sensorium registers new branch in UAE to expand global presence
By Mateen Dalal

Sensorium, developer of the Sensorium Galaxy metaverse, has registered its new branch in the United Arab Emirates (UAE) as Dubai gradually becomes a global hub for metaverse companies. The new entity, slated to be officially inaugurated in the com...